Novel 5'-norcarbocyclic adenine and guanine phosphonic acid analogues with 6'-electronegative moiety such as unsaturated C-C bond were designed and synthesized from commercially available 2-methylene-propane-1,3-diol (4). Regioselective Mitsunobu reaction successfully proceeded from an allylic functional group (±)-12b at low reaction temperature in polar cosolvent (DMF/1,4-dioxane) to give purine phosphonate analogues (±)-13 and (±)-20. The purine nucleoside phosphonate and phosphonic acid analogues were subjected to antiviral screening against HIV-1. Guanine analogue (±)-23 shows significant anti-HIV activity in PBM cell lines (EC 50 = 8.1 µM).
Introduction
Several phosphonate and phosphonic acid derivatives of purines and pyrimidines have emerged as potent antiviral agents.
1 The spacial location of the oxygen atom, namely the β-position from the phosphorus atom in the nucleoside analogue, plays a critical role in the antiviral activity. This increased antiviral activity with this oxygen atom may be attributed to the increased binding capacity of the phosphonate analogues to target enzymes. 2 Moreover, a phosphonate nucleoside analogue can skip the requisite first phosphorylation, which is a crucial step for the activation of nucleosides. 3 As mimics of nucleoside monophosphates, these nucleotide analogues exert their antiviral effect following sequential activation by cellular kinases to their diphosphate derivatives (nucleoside triphosphate analogues) which act as potent inhibitors of viral DNA polymerases. 4 A selective inhibition for these enzymes as opposed to host cell DNA polymerases is critical for the potential use of such compounds as drugs. Various attempts to improve the selectivity index have led to rigid nucleoside analogues modified in their cyclopentane ring system by introduction of unsaturations, sometimes with an exomethylene moiety in 6'-position.
Among these compounds, entecavir 5 1 is being clinically used as anti-HBV drugs (Figure 1 ). Pyrimidine isonucleoside 2 with a methylene 6 moiety in place of carbon atom of the furanose ring was reported to show antiviral activity, especially anti-HIV activity. The phosphonate analogue 3 was successfully prepared and evaluated for its inhibitory effect on the replication of retroviruses, including Rauchermurine Leukemia virus (R-MuLV) and HIV-1. Furthermore, compound 3 was superior to d4T in inhibiting R-MuLV at three orders magnitude low concentration, indicating that the murine model might be useful to evaluate 3 for its in vivo efficacy against the retrovirus.
7 Molecular modeling studies demonstrated the presence of an electronegative moiety at the 6'-position that could accommodate these substitutions and contribute to the observed enhancement in potency in anti-HIV activity. 8 Stimulated by these findings that 6'-electronegative nucleoside analogues and 5'-norcarbocyclic nucleoside phosphonates have excellent biological activities, we sought to synthesize a novel class of nucleosides comprising 6'-methylene-5'-norcarbocyclic phosphonic acid analogues in order to search for more effective therapeutics against HIV and to provide analogues for probing the conformational preferences of enzymes associated with the nucleoside kinases of nucleosides and nucleotides.
As depicted in Scheme 1, the target compounds were prepared from 2-methylene-propane-1,3-diol (4). Monosilylation of diol 4 and subsequent oxidation of corresponding allylic alcohol 5 gave α,β-unsaturated aldehyde 6. The aldehyde functional group of 6 was subjected to carbonyl addition reaction by vinylmagensium bromide 9 to furnish the secondary alcohol (±)-7, which was successfully protected using p-methoxybenzyl chloride (PMBCl) 10 to provide compound (±)-8. Removal of the silyl protecting group of (±)-8 using tetra n-butylammonium fluoride (TBAF) gave the primary alcohol (±)-9, which was oxidized to the aldehyde (±)-10 using same oxidation conditions as described for 6. The aldehyde (±)-10 was subjected to nucleophilic Grignard conditions with vinylmagnesium bromide to give divinyl (±)-11, which was subjected to ring-closing metathesis (RCM) conditions using 2 nd generation Grubbs catalyst (C 46 H 65 Cl 2 N 2 PRu) 11 to provide 6'-cyclopentenol (±)-12a (38%) and (±)-12b (39%), which were readily separated by silica gel column chromatography. The Nuclear Overhauser Enhancement (NOE) experiments with cyclopentenols (±)-12a and (±)-12b confirmed these assignments. As expected, NOE enhancements were found between the cis-oriented hydrogens. Upon irradiation of C 1 -H, weak NOE patterns were observed at the proximal hydrogens of compound (±)-
To synthesize the desired 5'-norcarbocyclic adenosine nucleoside analogues, the protected cyclopentenol (±)-12b was treated with 6-chloropurine under Mitsunobu conditions 12 (DEAD and PPh 3 ). The appropriate choice of solvent system, temperature and procedure are essential for the regioselectivity as well as for the yield. In purine synthesis, a mixture of dioxane and DMF were used as the solvent for the coupling of the cyclopentenol (±)-12b with 6-chloropurine instead of THF. The heterocyclic bases had a better solubility in the dioxane-DMF mixture resulting in better yields. Slow addition of diethyl azodicarboxylate (DEAD) to a mixture of cyclopentenol (±)-12b, triphenylphosphine and the 6-chloropurine in anhydrous cosolvent (dioxane-DMF) gave a yellow solution, which was stirred for 2.0 h at −40 °C and further stirred overnight at rt to give the protected 6-chloropurine analogue (±)-13 as an only N 9 -regioisomer [UV (MeOH) λ max 264.5 nm]. 13 The PMB protection group was removed with 2,3-dichloro-5,6-dicyano-p-benzoquinone (DDQ) 14 to produce the 5'-nornucleoside analogue (±)-14, which was treated with diethylphosphonomethyl triflate 15 using lithium t-butoxide to yield the nucleoside phosphonate analogue (±)-15 (Scheme 2). The chlorine group of (±)-15 was then converted to amine with methanolic ammonia at 65 o C to give the corresponding adenine phosphonate derivative (±)-16. Hydrolysis of (±)-16 by treatment with bromotrimethylsilane in CH 3 CN in the presence of 2,6-lutidine gave an adenine phosphonic acid derivative (±)-17 (Scheme 2).
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The cyclopentenol intermediate (±)-19 was also used for the synthesis of 2,6-disubstituted purine analogues such as guanine derivative (±)-23. Regioselective coupling of the enol (±)-19 with 2-fluoro-6-chloropurine 17 under the similar conditions for 6-chloropurine gives analogue (±)-20. Bubbling ammonia into the compound (±)-20 gave separable 2-fluoro-6-aminopurine 18 analogue (±)-21 (11%) and 2-amino-6-chloropurine analogue (±)-22 (57%), respectively. 2-Amino-6-chloropurine derivative (±)-22 was treated with TMSBr to provide phosphonic acid and sequentially treated sodium methoxide and 2-mercaptoethanol in methanol to give desired guanine phosphonic acid (±)-23 (Scheme 3).
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The synthesized nucleoside phosphonate and phosphonic acid analogues (±)-16, (±)-17, (±)-21, (±)-22 and (±)-23 were then evaluated for antiviral activity against human immunodeficiency virus. The procedures for measuring the antiviral activity toward wild-type HIV and cytotoxicity have been reported previously. 20 As shown in Table 1 , Figure 2 . NOE differences between the proximal hydrogens of (±)-12a and (±)-12b. guanine nucleoside phosphonic acid (±)-23 exhibits significant anti-HIV activity. However, nucleoside analogues (±)-16, (±)-17, (±)-21, and (±)-22 showed weak anti-HIV activity or cytotoxicity at concentrations up to 100 μM. In summary, based on the potent anti-HIV activity of 6'-electronegative nucleosides and 5'-norcarbocyclic nucleoside analogues, we have designed and successfully synthesized novel 6'-methylene-5'-norcarbocyclic nucleoside analogues starting from 2-methylene-propane-1,3-diol (4). The synthesized nucleotide guanine (±)-23 exhibited improvement in cell-based activity compared with adenine phosphonic acid (±)-17. Although the nucleotide analogue 3 inhibits in vitro anti-HIV activity, the carbocyclic versions shows weak anti-HIV activity except guanine analogue (±)-23. Since rigid cyclopentene carbocycles are not perfect mimics for ribofuranose moiety, the mechanisms of virus inhibition, that is, either phosphorylation or inhibition of RNA synthesis, might be impaired in these compounds. Homologation of 6'-position is another possible reason for the apparent lack of activity. Figure 3 shows the superposition of the calculated low energy conformers of 3 and 17, highlighting the two difference parts such as purine bases and phosphonic acid functional moieties.
Experimental Section
Melting points were determined on a Mel-temp II laboratory device and are uncorrected. NMR spectra were recorded on a JEOL 300 Fourier transform spectrometer (JEOL, Tokyo, Japan); chemical shifts are reported in parts per million (δ) and signals are reported as s (singlet), d (doublet), t (triplet), q (quartet), m (multiplet) and dd (doublet of doublets). UV spectra were obtained on a Beckman DU-7 spectrophotometer (Beckman, South Pasadena, CA, USA). MS spectra were collected in electrospray ionization (ESI) mode. The elemental analyses were performed using a Perkin-Elmer 2400 analyzer (Perkin-Elmer, Norwalk, CT, USA). TLC was performed on Uniplates (silica gel) purchased from Analtech Co. (7558, Newark, DE, USA). All reactions were carried out under an atmosphere of nitrogen unless otherwise specified. Dry dichloromethane, benzene and pyridine were obtained by distillation from CaH 2 . Dry THF was obtained by distillation from Na and benzophenone immediately prior to use.
2-(t-Butyldimethylsilanyloxymethyl)prop-2-en-1-ol (5). To a stirred solution of compound 4 (3.5 g, 39.72 mmol) and imidazole (4.05 g, 59.58 mmol) in CH 2 Cl 2 (150 mL), tbutyldimethylsilyl chloride (6.28 g, 41.7 mmol) was added at 0 o C. The mixture was stirred at the same temperature for 4 h, and quenched by adding a NaHCO 3 aqueous solution (10 mL). The mixture was extracted using EtOAc (200 mL), dried over MgSO 4 , filtered and then concentrated. The residue was purified by silica gel column chromatography (EtOAc/hexane, 1:7) to give 5 (6.27 g, 78%) as a colorless syrup:
1 H NMR ( 2-(t-Butyldimethylsilanyloxymethyl)propenal (6) . To a mixture of allylic alcohol 5 (838 mg, 4.14 mmol), manganese (IV) dioxide (1.08 g, 12.4 mmol) and CCl 4 (12 mL) was added and refluxed overnight. Additional manganese (IV) dioxide (180 mg, 2.06 mmol) was added and refluxed for an additional 12 h. The progress of the reaction was monitored by TLC. The resulting mixture was filtered through a pad of celite, washed with ethyl acetate. The filtrate and washings were condensed in vacuo and the residue was purified by silica gel column chromatography (EtOAc/hexane, 1:15) to give α,β-unsaturated aldehyde 6 (622 mg, 75%) as a colorless oil. Saturated NH 4 Cl solution (10 mL) was added to the mixture, which was slowly warmed to rt. The mixture was diluted with water (100 mL) and extracted with EtOAc (2 × 100 mL). The combined organic layer was washed with brine, dried over anhydrous MgSO 4 , filtered, and evaporated in vacuo. The residue was purified by silica gel column chromatography (EtOAc/hexane, 1:15) to give 7 (1.34 g, 76%) as a colorless oil: (8) . NaH (60% in mineral oil, 131 mg, 3.32 mmol) was added portion-wise to a cooled (0°C ) solution of secondary alcohol 7 (632 mg, 2.77 mmol) and p-methoxybenzyl chloride (0.41 mL, 3.04 mmol) in anhydrous DMF (10 mL). The reaction mixture was stirred overnight at rt. The solvent was removed in vacuo and the residue was diluted with H 2 O (70 mL) followed by extraction with diethyl ether (2 × 70 mL). The combined organic layer was washed with brine, dried over anhydrous MgSO 4 , and concentrated under vacuum. The residue was purified by silica gel column chromatography (EtOAc/ hexane, 1:15) to give 8 (675 mg, 70%) as a colorless oil. (±)-3-(4-Methoxybenzyloxy)-2-methylenepent-4-enal (10). Aldehyde derivative 10 was synthesized from 9 by the similar procedure as described for 6: yield 78%; (rel)-(1R,4S)-9-(4-Hydroxy-5-methylene-cyclopent-2-en-1-yl)-6-chloropurine (14) . To a solution of compound 13 (156 mg, 0.423 mmol) in CH 2 Cl 2 /H 2 O (8 mL, 10:1 v/v) was added DDQ (143 mg, 0.623 mmol), and the mixture was stirred overnight at room temperature. Saturated NaHCO 3 (0.8 mL) was added to quench the reaction, which was then stirred for 2 h at rt. The mixture was diluted with water (100 mL) and extracted with CH 2 Cl 2 (3 × 100 mL). The combined organic layer was dried over anhydrous MgSO 4 and filtered. The filtrate was concentrated in vacuo and the residue was purified by silica gel column chromatography (rel)-(1'S,4'R)-Diethyl [9-(4-hydroxy-5-methylene-cyclopent-2-en-1-yl)-2-fluoro-6-aminopurine]phosphonate (21) and (rel)-(1'S,4'R)-diethyl [9-(4-hydroxy-5-methylenecyclopent-2-en-1-yl)-2-amino-6-chloropurine]phosphonate (22). Dry ammonia gas was bubbled into a stirred solution of 20 (850 mg, 2.40 mmol) in DME (45 mL) at room temperature overnight. The salts were removed by filtration and the filtrate was concentrated under reduced pressure. (rel)-(1'S,4'R)-9-(4-Hydroxy-5-methylene-cyclopent-2-en-1-yl)guanine]phosphonic Acid (23). To a solution of 22 (13.6 mg, 0.033 mmol) dry DMF (4 mL) was added trimethylsilyl bromide (75.9 mL, 0.575 mmol) at room temperature. After this mixture was stirred for 2 days, the solvent was removed, coevaporating three times with methanol. The residue was dissolved in MeOH (1.0 mL) and 2-mercaptoethanol (9 mL, 0.132 mmol) and NaOMe (7 mg, 0.132 mmol) was added to the mixture. The mixture was refluxed for 4 h under N 2 , cooled, neutralized with glacial AcOH, and evaporated to dryness under vacuum. The residue was purified by chromatography on a column of reversed-phase C18 silica gel eluting water to give 23 (6.8 mg, 61%) as a white solid. UV (H 2 O) λ max 253.0 nm; 
